Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis

Shijubo, Noriharu; Imai, Kohzoh; Aoki, Shigeo; Hirasawa, Michio; Sugawara, Hiroyuki; Tsujisaki, Masayuki; Sugiyama, T.; Hinoda, Yuji; Yachi, Akira; Asakawa, Mitsuo; Suzuki, Asako

doi:10.1111/j.1365-2249.1992.tb06877.x

Cited by 79 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ICAM-1 is expressed on a variety of cells, including leucocytes and endothelial cells [7], and may be released from both these sources on activation in vitro [8,23,24]. Increased levels of ICAM-1 have been reported in the serum of patients with uveitis, including some with sarcoidosis [14], malignant melanoma [16], Kawasaki disease [18], chronic liver disease [15], rheumatoid arthritis [13], idiopathic pulmonary fibrosis [ 17] and leucocyte adhesion deficiency [8]. No differences were seen in VCAM-1 expression between patients and controls.…”

Section: Discussionmentioning

confidence: 99%

“…Other molecules are the fiX integrins such as VLA-4, selectins such as E-selectin (ELAM-1) and members of the immunoglobulin supergene family such as intercellular adhesion molecule-l (ICAM-1), -2, and -3 and vascular cell adhesion molecule-1 (VCAM-1). In addition to the cell surface expression of these molecules, there are now several reports showing that circulating soluble adhesion proteins are present in normal serum [8][9][10][11][12] and that the levels of these molecules may rise in disease [8][9][10][11][12][13][14][15][16][17][18][19]. It is likely that the levels of the cytokine-inducible cell adhesion molecules E-selectin, VCAM-I and ICAM-1 reflect the degree of cellular activation and turnover of cellular antigens.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating adhesion molecules in sarcoidosis

Hamblin

Shakoor

Kapahi

et al. 1994

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYSarcoidosis is a disease of unknown etiology characterized by non-caseating granulomata together with a number of systemic abnormalities. We have recently shown these include increased expression of the integrins CDl 1/CD18 on peripheral blood leucocytes. Here we have measured serum levels of the adhesion molecules intercellular adhesion molecule-l (ICAM-1), E-selectin and vascular cell adhesion molecule-l (VCAM-1) in 23 patients and 14 normal controls using antigen capture sandwich ELISAs. Median circulating E-selectin levels in the patients were nearly three times those of thecontrols(P< 00001, Mann-Whitney [/-test), whilst ICAM-I butnotVCAM-l levels were only slightly elevated. These results show that endothelial cell activation and shedding of E-selectin into the circulation are additional features of the pathology of sarcoidosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Circulating adhesion molecules in sarcoidosis

Hamblin

Shakoor

Kapahi

et al. 1994

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…wt 82000 has been described that binds LFA-1 and blocks rhinovirus infection [23]. Shedding of ICAM-I has been induced in vitro following treatment of melanoma cells or endothelial cells with certain cytokines [24][25][26], //(vivo, elevated serum concentrations forsICAM-l and the correlation of slCAM-1 serum levels with immunologic disease activity have been reported in autoimmune vascular and endocrine diseases [27.,2y3, inflammatory fibrogenic conditions [29] and certain cancers [24,30].…”

Section: Introductionmentioning

confidence: 99%

Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves’ ophthalmopathy and thyroid diseases

Heufelder

Bahn

1993

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARY Intercellular adhesion molecule, a ligand for the leucocyte integrins CDlla/CD18 (LFA‐1) and CD11b/CD18 (Mac‐1), that plays an important role in a variety of inflammatory and immune‐mediated mechanisms, is strongly expressed in rctroocular connective tissue from patients with Graves’ ophthalmopathy (GO) and involved in lymphocyte attachment to cultured retroocular fibroblasts via the ICAM‐1/LFA‐1‐mediated pathway. Here, we report the detection and functional activity of a soluble form of the ICAM‐1 molecule (sICAM‐1) in sera from patients with GO and other thyroid diseases. Serum concentrations for sICAM‐1 were determined using a highly sensitive ELISA. Compared with normal controls, patients with hyperthyroid or euthyroid GO and patients with Riedcl's invasive fibrous thyroiditis revealed markedly elevated sICAM‐1 serum concentrations (all P 0.0001). In patients with Graves’ disease (GD) without clinical GO and in patients with Hashimoto's thyroiditis (HT), sICAM‐1 levels were elevated to a lesser degree (both P < 0.001). sICAVI‐l serum levels in patients with non‐autoimmune hyperthyroidism due to a toxic adenoma were not significantly different from normal controls. In a separate group of 12 patients with severe inflammatory GO, sICAM‐1 serum levels markedly declined (P < 0.0001) within 3 months of glucocorticoid therapy in nine patients who responded to this form of treatment with a decrease in periorbital inflammation. In contrast, sICAM‐1 serum levels remained unchanged in three patients with poor response to steroids and persistent inflammatory periorbital disease. When tested in a cell adhesion assay, GO sera containing elevated concentrations of sICAM‐1 were found to enhance the attachment of peripheral blood mononuclear cells (PBMC) to interferon‐gamma (IFN‐γ)‐treated retroocular fibroblasts in a dose‐dependent manner, up to a maximal stimulation of approximately 5×5‐fold (P 0.001). This effect was abolished by preabsorption of sera with a MoAb against ICAM‐1 and inhibited, in a dose‐dependent manner, by coincubation with increasing concentrations of purified sICAM‐1. In conclusion, sICAM‐1 concentrations are markedly elevated in sera from patients with GO, and changes in sICAM‐1 serum levels during glucocorticoid therapy closely parallel changes in the degree of inflammation. Given the capacity of sICAM‐l to modulate the adhesion of lymphocytes to retroocular fibroblasts in vitro, sICAM‐1 may play a role in the ongoing immune process within the connective tissue in GO.

show abstract

“…Additional immunohistochemistry analysis on lung tissue from the IPF patients demonstrated expression of ICAM-1 on alveolar epithelial cells. 91 A follow-up study investigated the serum and BALF levels of ICAM-1 in IPF patients and again found significant elevations in the serum of IPF patients compared to both sarcoidosis patients and healthy volunteers, although BALF levels in IPF patients were not significantly elevated. 92 In another study of the serum levels of several ICAM proteins in IPF, the authors found both ICAM-1 and ICAM-2 to be significantly elevated in IPF patients and secondary ILD patients.…”

Section: Intercellular Adhesion Molecule-1mentioning

confidence: 99%

Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way of understanding disease pathogenesis

Flynn¹,

Baker²,

Kass

2015

CBF

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a typically fatal disease that remains incompletely understood despite intense study and the arrival of drugs that may alter the natural history of the disease. Rendering an accurate diagnosis and predicting prognosis remain challenging problems to clinicians. One potential solution to these clinical problems is the identification of IPF biomarkers, easily measured factors that can be employed to predict clinical behavior. Candidate biomarkers have been identified by research in the laboratory on potential culprit cells or genes that may contribute to the pathogenesis of IPF. In this review, we present the current data on a number of well-studied IPF biomarker candidates and their potential role in the pathogenesis of disease. We also establish a framework for evaluating utility of incorporating these IPF biomarkers into clinical practice.

show abstract

Circulating intercellular adhesion molecule-1 (ICAM-1) antigen in sera of patients with idiopathic pulmonary fibrosis

Cited by 79 publications

References 23 publications

Circulating adhesion molecules in sarcoidosis

Circulating adhesion molecules in sarcoidosis

Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves’ ophthalmopathy and thyroid diseases

Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way of understanding disease pathogenesis

Contact Info

Product

Resources

About